The Effect of Personalized Exercise Interventions for the Prevention of Chemotherapy-induced Peripheral Neuropathy

What this Trial Is About

Chemotherapy-induced peripheral neuropathy (CIPN) is a common and disabling side effect of neurotoxic cancer treatments, causing sensory problems and weakness in the hands and feet. This condition can disrupt daily activities and affect cancer treatment. Researchers are evaluating whether a personalized exercise program following international physical activity guidelines can help prevent CIPN symptoms in patients with breast or colorectal cancer undergoing taxane- or platinum-based chemotherapy. The study also explores how patients and healthcare providers experience integrating physical activity during treatment. Participants are randomly assigned to either a 12-week personalized exercise program combined with usual care or to usual care alone, which includes advice on physical activity during cancer treatment. The exercise program involves a 30-minute one-on-one session with a physiotherapist explaining the importance of physical activity, followed by home-based aerobic exercise three times a week and supervised resistance and sensorimotor exercises twice a week. The study focuses on the short-term effects at 12 weeks and longer-term effects at 24 weeks. During the study, participants undergo various assessments including questionnaires on CIPN symptoms, physical and psychosocial functioning, pain, fatigue, sleep, mood, social participation, cognitive function, and quality of life. Researchers will also monitor chemotherapy dose intensity and physical activity levels. The main outcome is the severity of sensory CIPN symptoms at 12 weeks, with follow-up evaluations extending to 24 weeks. The study will also evaluate how well participants stick to the exercise program and gather feedback from patients and healthcare professionals on its implementation.

The Effect of Personalized Exercise Interventions for the Prevention of Chemotherapy-induced Peripheral Neuropathy